The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.» Read More
Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.
Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.
Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.
NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.
Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.
April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.
Spending on medicines rose 3.2 percent in the United States last year to $329.2 billion.
Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.
Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.
Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.
BlackBerry Ltd. fell 1.9 percent to $7.14 with 17,696,100 shares traded. Cisco Systems Inc. rose 1.7 percent to $22.85 with 35,296,700 shares traded. Facebook Inc. rose. 6 percent to $58.89 with 70,744,500 shares traded.
Amgen Inc. rose$. 01 or percent, to $111.95. Biogen Idec rose $3.06 or 1.1 percent, to $277.06. Celgene Corp. rose $1.60 or 1.2 percent, to $138.50.
Amgen Inc. fell $2.17 or 1.9 percent, to $111.94. Biogen Idec fell $13.35 or 4.6 percent, to $274.00. Celgene Corp. fell $3.08 or 2.2 percent, to $136.90.
Cisco Systems Inc. fell. 8 percent to $22.46 with 47,023,900 shares traded. Facebook Inc. fell 1.1 percent to $58.53 with 85,527,500 shares traded. Gilead Sciences Inc. rose. 8 percent to $66.03 with 35,640,900 shares traded.
*JPMorgan falls, Wells Fargo gains after results. NEW YORK, April 11- U.S. stocks were little changed on Friday, as biotech stocks staged a rebound from a selloff in the prior session, but disappointing earnings from JPMorgan curbed gains.
*JPMorgan falls, Wells Fargo flat after results. NEW YORK, April 11- U.S. stocks were set for a lower open on Friday after earnings from JP Morgan Chase, putting the S&P 500 on track to continue its selloff after suffering its biggest drop in two months.
LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.
The Nasdaq composite fell 3 percent, its worst drop since November 2011. Gilead Sciences was among the big biotech names to take a beating, giving up 7 percent. Facebook, which also doubled last year, sank 5 percent.
*VIX, Wall Street's fear index, jumps 15 percent. NEW YORK, April 10- The Nasdaq suffered its biggest drop in two-and-a-half years on Thursday after another sharp selloff in biotech and momentum names, including Gilead Sciences and TripAdvisor, increasing investor anxiety about a broader pullback.
*Biotech index has worst day since August 2011. NEW YORK, April 10- The Nasdaq suffered its biggest drop in two-and-a-half years on Thursday after another sharp selloff in biotech and momentum names, including Gilead Sciences and TripAdvisor, increasing investor anxiety about a broader pullback.